A patient was given anti- cancer therapy and developed neutropenia which of the following drug can be used to prevent neutropenia in next cycle of chemotherapy?
**Core Concept**
Neutropenia is a common side effect of chemotherapy, characterized by a decreased count of neutrophils, a type of white blood cell essential for fighting infections. The goal of prophylactic measures is to prevent this condition, ensuring the patient can receive subsequent cycles of chemotherapy without interruption.
**Why the Correct Answer is Right**
G-CSF (Granulocyte-Colony Stimulating Factor) is a recombinant protein that stimulates the production of neutrophils in the bone marrow. When administered before chemotherapy, G-CSF can help prevent neutropenia by increasing the neutrophil count, thereby reducing the risk of infections. This is particularly useful in patients undergoing chemotherapy for cancer, where neutropenia can lead to life-threatening complications.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is likely a placeholder or incorrect. There is no well-known medication that directly prevents neutropenia by a different mechanism.
**Option B:** This option might refer to a different medication, but it is not the correct answer. Other growth factors like GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) can stimulate the production of various white blood cells but are not the primary choice for preventing neutropenia.
**Option D:** This option is incorrect as it does not directly address the prevention of neutropenia. Other medications like antibiotics may be used to prevent infections in neutropenic patients but do not stimulate the production of neutrophils.
**Clinical Pearl / High-Yield Fact**
G-CSF can be used in patients with a history of severe neutropenia or those at high risk of neutropenia. It is essential to note that G-CSF should be started before the next cycle of chemotherapy, and the patient's neutrophil count should be monitored regularly.
**Correct Answer:** C. G-CSF can be used to prevent neutropenia in the next cycle of chemotherapy.